MAP3K7 and cancer: TAK1 was first identified as a TGF-β-activated kinase (1), and over the years it has been shown to respond to a number of internal and external stimuli to phosphorylate a wide range of downstream targets and trigger diverse cellular responses in a variety of diseases, including cancers and neurodegenerative diseases (2–5).